Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: A meta-analysis
- PMID: 29023491
- PMCID: PMC5638411
- DOI: 10.1371/journal.pone.0186180
Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: A meta-analysis
Abstract
Background: Carbonic anhydrase inhibitors (CAI) are often used in the treatment of cystoid macular edema (CME) in retinitis pigmentosa (RP) patients. The aim of this meta-analysis is to gain a better understanding of the overall efficacy of CAI treatment.
Methods: Databases including PubMed, EMBASE, and Cochrane Library were searched to identify relevant studies. Eligible studies were clinical trials of patients with RP assigned topical or oral CAIs such as dorzolamide and acetazolamide. Changes in central macular thickness (CMT) by OCT in μm and best-corrected visual acuity (BCVA) in log MAR equivalents were extracted and results compared between baseline and after treatment.
Results: 11 clinical reports were identified which included a total of 194 patients (358 eyes) available for analysis, with 59 patients (115 eyes) assigned oral CAI treatment and 135 patients (243 eyes) assigned topical CAI treatment. The combined results showed a significant reduction of macular edema, as calculated by baseline and final central macular thickness (CMT) based on OCT examination (46.02μm, 95%CI: -60.96, -31.08, I2 = 65%). However, the effect on visual acuity was inconsistent across studies.
Conclusion: Based on non randomized controlled clinical studies, RP patients with CME who were treated with CAIs had better anatomical outcomes, but the effect on visual acuity was contradictory across studies. Multicenter prospective randomized controlled trials would be ideal to definitively test its clinical efficacy in RP patients.
Conflict of interest statement
Figures
Similar articles
-
Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa.Retina. 1997;17(3):222-31. doi: 10.1097/00006982-199705000-00009. Retina. 1997. PMID: 9196934 Clinical Trial.
-
Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa.Invest Ophthalmol Vis Sci. 2015 Feb 10;56(3):1531-6. doi: 10.1167/iovs.14-15995. Invest Ophthalmol Vis Sci. 2015. PMID: 25670491
-
The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa.Graefes Arch Clin Exp Ophthalmol. 2012 Jun;250(6):809-14. doi: 10.1007/s00417-011-1904-5. Epub 2012 Jan 4. Graefes Arch Clin Exp Ophthalmol. 2012. PMID: 22215259
-
Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review.Surv Ophthalmol. 2018 May-Jun;63(3):329-339. doi: 10.1016/j.survophthal.2017.09.009. Epub 2017 Oct 5. Surv Ophthalmol. 2018. PMID: 28987613 Review.
-
The effect of an intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa: a case report and literature review.Ophthalmic Surg Lasers Imaging Retina. 2014 Mar-Apr;45(2):160-4. doi: 10.3928/23258160-20140131-03. Epub 2014 Feb 7. Ophthalmic Surg Lasers Imaging Retina. 2014. PMID: 24506098 Review.
Cited by
-
Open-Angle and Steroid-Induced Glaucoma in Patients With Retinitis Pigmentosa: A Dangerous Liaison.Cureus. 2024 Mar 6;16(3):e55632. doi: 10.7759/cureus.55632. eCollection 2024 Mar. Cureus. 2024. PMID: 38586746 Free PMC article.
-
Carbonic anhydrase inhibitors in the management of macular edema: A review of the literature.Med Hypothesis Discov Innov Ophthalmol. 2022 Apr 1;11(1):34-41. doi: 10.51329/mehdiophthal1443. eCollection 2022 Spring. Med Hypothesis Discov Innov Ophthalmol. 2022. PMID: 37641698 Free PMC article. Review.
-
Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies.Int J Mol Sci. 2023 Apr 19;24(8):7481. doi: 10.3390/ijms24087481. Int J Mol Sci. 2023. PMID: 37108642 Free PMC article. Review.
-
Management of Cystoid Macular Edema in Retinitis Pigmentosa: A Systematic Review and Meta-Analysis.Front Med (Lausanne). 2022 May 16;9:895208. doi: 10.3389/fmed.2022.895208. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35652079 Free PMC article.
-
Frequency of cystoid macular edema and vitreomacular interface disorders in genetically solved syndromic and non-syndromic retinitis pigmentosa.Graefes Arch Clin Exp Ophthalmol. 2022 Sep;260(9):2859-2866. doi: 10.1007/s00417-022-05649-y. Epub 2022 Apr 7. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35389060
References
-
- Rosenberg T, Haim M, Hauch AM, Parving A. The prevalence of Usher syndrome and other retinal dystrophy-hearing impairment associations. Clin Genet. 1997;51(5):314–21. Epub 1997/05/01. . - PubMed
-
- Salvatore S, Fishman GA, Genead MA. Treatment of cystic macular lesions in hereditary retinal dystrophies. Surv Ophthalmol. 2013;58(6):560–84. Epub 2013/10/29. doi: 10.1016/j.survophthal.2012.11.006 . - DOI - PubMed
-
- Fishman GA, Maggiano JM, Fishman M. Foveal lesions seen in retinitis pigmentosa. Arch Ophthalmol. 1977;95(11):1993–6. Epub 1977/11/01. . - PubMed
-
- Fishman GA, Fishman M, Maggiano J. Macular lesions associated with retinitis pigmentosa. Arch Ophthalmol. 1977;95(5):798–803. Epub 1977/05/01. . - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical